Mutation analysis of factor VIII in Korean patients with severe hemophilia A

被引:7
作者
You, Chur-Woo [5 ]
Son, Hee-Sook [5 ]
Kim, Hee Jin [4 ]
Woo, Eui-Jeon [3 ]
Kim, Soon-Ae [2 ]
Baik, Haing-Woon [1 ]
机构
[1] Eulji Univ, Sch Med, Dept Biochem & Mol Biol, Taejon 301832, South Korea
[2] Eulji Univ, Sch Med, Dept Pharmacol, Taejon 301832, South Korea
[3] Korea Res Inst Biosci & Biotechnol, Translat Res Ctr, Taejon, South Korea
[4] Sungkyunkwan Univ, Sch Med, Dept Lab Med, Seoul, South Korea
[5] Eulji Univ, Sch Med, Dept Pediat, Taejon 301832, South Korea
关键词
Severe hemophilia A; Korean; Factor VIII; Mutation; INHIBITOR DEVELOPMENT; INVERSION HOTSPOT; MOLECULAR-BASIS; GENE; IDENTIFICATION; SITE; POLYMORPHISMS; RECOMBINANT; DIAGNOSIS; RESIDUES;
D O I
10.1007/s12185-010-0593-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hemophilia A is an X-linked recessive disorder caused by mutations of the factor VIII gene. The mutation spectrum has been reported in various populations, but not in Koreans. Mutation analysis of the factor VIII gene was performed in 22 unrelated Korean patients with severe hemophilia A. We extracted genomic DNA from their blood, and assessed intron inversions, deletions, and point mutations by direct DNA sequencing. A multiplex ligation-dependent probe amplification gene dosage assay was also performed to identify exon deletions. Disease-causing mutations were identified in all patients, of which four cases were previously unreported. Seven intron 22 inversions, nine point mutations (6 nonsense mutations and 3 missense mutations), and four small rearrangements were identified. One multi-exon deletion and one 5'-donor splicing site mutation were also observed. Four novel mutations (one small deletion, one multiple exon deletion, one missense, and one splice site mutation) were detected, and point mutations were predominant (40.9%), followed by intron 22 inversions (31.8%). Further studies are required in order to establish a solid conclusion regarding the prevalence of various mutations in the Korean population.
引用
收藏
页码:784 / 791
页数:8
相关论文
共 50 条
  • [21] Prevalence of factor VIII inhibitors among Afghan patients with hemophilia A: a first report
    Mousavi, Sayed H.
    Mesbah-Namin, Seyed A.
    Rezaie, Nematullah
    Jazebi, Mohammad
    Zeinali, Sirous
    BLOOD COAGULATION & FIBRINOLYSIS, 2018, 29 (08) : 697 - 700
  • [22] Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A
    Repesse, Yohann
    Costa, Catherine
    Palla, Roberta
    Moshai, Elika Farrokhi
    Borel-Derlon, Annie
    D'Oiron, Roseline
    Rothschild, Chantal
    El-Beshlawy, Amal
    Elalfy, Mohsen
    Ramanan, Vijay
    Eshghi, Peyman
    Oldenburg, Johannes
    Pavlova, Anna
    Rosendaal, Frits R.
    Peyvandi, Flora
    Kaveri, Srinivas V.
    Lacroix-Desmazes, Sebastien
    HAEMATOLOGICA, 2019, 104 (08) : E369 - E372
  • [23] Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
    Han, Jeong Pil
    Song, Dong Woo
    Lee, Jeong Hyeon
    Lee, Geon Seong
    Yeom, Su Cheong
    BIOLOGY-BASEL, 2021, 10 (08):
  • [24] The prevalence of factor VIII inhibitor in patients with severe hemophilia-A and its clinical characteristics
    Harijadi
    Gatot, Djajadiman
    Akib, Arwin A. P.
    PAEDIATRICA INDONESIANA, 2005, 45 (7-8) : 177 - 181
  • [25] Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A
    Zhang, Y.
    Roberts, J.
    Tortorici, M.
    Veldman, A.
    St Ledger, K.
    Feussner, A.
    Sidhu, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (06) : 1106 - 1114
  • [26] Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
    Sherief, Laila M.
    Gaber, Osama A.
    Youssef, Hala Mosaad
    Sherbiny, Hanan S.
    Mokhtar, Wesam a
    Ali, Asmaa A. A.
    Kamal, Naglaa M.
    Abdel Maksoud, Yehia H.
    ITALIAN JOURNAL OF PEDIATRICS, 2020, 46 (01)
  • [27] Factor VIII assays in treated hemophilia A patients
    Lasne, Dominique
    Pouplard, Claire
    Nougier, Christophe
    Eschwege, Valerie
    Duchez, Veronique Le Cam
    Proulle, Valerie
    Smahi, Motalib
    Harzallah, Ines
    Voisin, Sophie
    Toulon, Pierre
    Sobas, Frederic
    Galinat, Hubert
    Flaujac, Claire
    Ternisien, Catherine
    Jeanpierre, Emmanuelle
    HEMATOLOGIE, 2019, 25 (06): : 298 - 315
  • [28] The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A
    McEneny-King, A.
    Chelle, P.
    Iorio, A.
    Edginton, A. N.
    THROMBOSIS RESEARCH, 2018, 170 : 53 - 59
  • [29] Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review
    Hassan, S. .
    Cannavo, A.
    Gouw, S. C.
    Rosendaal, F. R.
    van der Bom, J. G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (06) : 1055 - 1068
  • [30] Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
    Gouw, Samantha C.
    van den Berg, H. Marijke
    Fischer, Kathelijn
    Auerswald, Guenter
    Carcao, Manuel
    Chalmers, Elizabeth
    Chambost, Herve
    Kurnik, Karin
    Liesner, Ri
    Petrini, Pia
    Platokouki, Helen
    Altisent, Carmen
    Oldenburg, Johannes
    Nolan, Beatrice
    Perez Garrido, Rosario
    Mancuso, M. Elisa
    Rafowicz, Anne
    Williams, Mike
    Clausen, Niels
    Middelburg, Rutger A.
    Ljung, Rolf
    van der Bom, Johanna G.
    BLOOD, 2013, 121 (20) : 4046 - 4055